BridgeBio Pharma (NASDAQ:BBIO) reported first-quarter 2026 results highlighted by continued growth for ATTRUBY and increased investment to support three anticipated launches, while also announcing a ...
Primary results from CALIBRATE, the Phase 3 registrational clinical trial of encaleret, will be shared in an oral presentation at the 2026 European Congress of Endocrinology (ECE) on May 12, 2026 at ...
6h
BridgeBio Pharma, Inc.: BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial momentumContinued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results